drugset / Trial / NCT00683657

Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

NCT00683657 ↗

Phase 3 Completed 93 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

This protocol will compare 24 hour glucose control for subject taking saxagliptin and metformin extended release (XR) versus metformin XR alone

Timeline

Start
2008-07
Primary completion
2009-02
Completion
2009-02

Outcome

Met primary endpoint

registry Saxagliptin 5 mg + Metformin vs Placebo + Metformin; p = 0.0001; Mean Difference (Final Values) -16.8 (95% CI -25.1 to -8.5) NCT00683657 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral